Alginate-based thermal genetics CXCL12 releaser as well as preparation method and application thereof

Through the alginate-based thermogenetics CXCL12 releaser combined with the thermogenetics CXCL12 genetically engineered cells and porous magnetic scaffolds, the alternating magnetic field activates CXCL12 release, solving the chemotherapy resistance and immune escape problems in the treatment of peritoneal metastasis in gastric cancer, realizing the Effective DTC recruitment and abdominal immune activation were inhibited.

CN118976106AActive Publication Date: 2024-11-19HUNAN UNIV
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411041485.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-19
Estimated Expiration
2044-07-31

AI Technical Summary

Technical Problem

The prior art chemotherapy resistance and side effects are serious in the treatment of peritoneal metastasis of gastric cancer, and there are challenges in immune escape and time-consuming adoptive cell therapy, making it difficult to effectively clear diffuse tumor cells (DTCs) and promote anti-tumor immune response.

Method used

Using an alginate-based thermogenetic CXCL12 releaser, by combining thermogenetic CXCL12 genetically engineered cells with porous magnetic scaffolds, the cells are activated by alternating magnetic fields to release CXCL12 chemokines, promoting DTC recruitment and abdominal immune activation.

Benefits of technology

Controllable CXCL12 release is achieved, which enhances the abdominal immune response against DTC, inhibits the abdominal metastasis of DTC, simplifies the preparation process and has the potential for large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976106A_ABST
    Figure CN118976106A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biomedicine, and provides an alginate-based thermal genetics CXCL12 releaser as well as a preparation method and application thereof. The alginate-based thermal genetics CXCL12 releaser (ATCG) based on an optimized alternating magnetic field is prepared by utilizing transgenic and freeze-drying technologies, the preparation is convenient and simple, the large-scale production can be realized, the ATCG consists of a porous magnetic bracket loaded with engineering cells, the engineering cells are stably transformed into a thermal genetics element of pHSP70-CXCL12 by lentivirus, and the ATCG can be used for preparing the thermal genetics CXCL12 releaser. According to the porous magnetic support, a main body frame structure is formed by a biopolymer material wrapped with magnetic particles, the porous magnetic support is of an isotropic porous structure, and the ATCG prepared through the method can controllably release CXCL12 chemotactic factors for DTC recruitment and activate anti-DTC abdominal immunity after magnetic thermal ablation, so that DTC abdominal metastasis is inhibited.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to an alginate-based thermogenetic CXCL12 releaser and a preparation method and application thereof. Background Art

[0002] Peritoneal metastasis is a clinical symptom of gastric cancer and is accompanied by a high risk of death. It is characterized by the production of large amounts of malignant ascites, abdominal pain, adhesive intestinal obstruction, nausea and vomiting. This condition is observed in more than 50% of patients at the time of death. Gastric cancer cells (called disseminated tumor cells, DTC) tend to metastasize to ascites due to physiological and anatomical characteristics and cell mutations. Therefore, clearing DTC in the peritoneum can prevent metastasis. Although conventional intraperitoneal chemotherapy and primary cytoreduction surgery are clinically accepted treatments for peritoneal metastasis, chemotherapy resistance and severe side effects still hinder widespread clinical application.

[0003] In recent years, intraperitoneal immunotherapy (IPIT) has been considered a promising strategy to improve the immune cold environment and produce effective immunity due to the unique chamber environment and abundant immune cells in the peritoneal cavity. However, IPIT still faces major challenges in immune escape caused by DTC dormancy and time-consuming adoptive cell therapy. Various immune cells and chemokines (CXCL12, CCL2) are involved in the dormancy and recruitment of DTCs and accelerate the development and accurate localization of cancer. Therefore, it is of great significance to design a material to promote controllable chemokine release in vivo and induce downstream anti-DTC immunity. Summary of the invention

[0004] The purpose of the present invention is to overcome the problems existing in the prior art and to provide an alginate-based thermogenetic CXCL12 releaser and a preparation method and application thereof.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides a method for preparing an alginate-based thermogenetic CXCL12 releaser, comprising the following steps:

[0007] (1) mixing a first biopolymer material solution, a first magnetic particle solution and a cross-linking agent to perform cross-linking to obtain a porous magnetic scaffold;

[0008] Alternatively, the second biopolymer material solution and the second magnetic particle solution are mixed and heated, and after the heating is completed, self-assembly and freeze-drying are performed in sequence to obtain a porous magnetic scaffold;

[0009] (2) Adding thermogenetic CXCL12 genetically engineered cells to the surface of the porous magnetic support for co-incubation to obtain the alginate-based thermogenetic CXCL12 releaser.

[0010] Preferably, in step (1), the first biopolymer in the first biopolymer material solution comprises sodium alginate, oxidized hyaluronic acid, chitosan or silk fibroin;

[0011] The first magnetic particles in the first magnetic particle solution include iron-cobalt graphite nanocapsules, ferrite particles, neodymium-iron-boron particles or alloy particles containing iron, cobalt and nickel; the mass concentration of the first magnetic particle solution is 8-12 mg / mL.

[0012] Preferably, when the first biopolymer material is sodium alginate, the method for preparing the porous magnetic scaffold comprises the following steps:

[0013] The sodium alginate solution, the first magnetic particle solution and the first cross-linking agent are mixed to perform a first cross-linking, and after the first cross-linking is completed, freeze-dried to obtain an intermediate substance; the intermediate substance is mixed with a second cross-linking agent to perform a second cross-linking to obtain a porous magnetic scaffold;

[0014] The mass fraction of the sodium alginate solution is 1.5-2.5%; the first cross-linking agent is a calcium gluconate solution, the mass fraction of the calcium gluconate solution is 0.5-1.0%; the second cross-linking agent is a calcium chloride solution, the concentration of the calcium chloride solution is 0.5-1.5 mol / L; the volume ratio of the sodium alginate solution, the first magnetic particle solution and the calcium gluconate solution is 1-3:0.5-1.5:0.5-1.5;

[0015] The temperature of the first cross-linking is 20-30°C, and the time of the first cross-linking is 10-15 minutes; the temperature of freeze-drying is -15--25°C, and the time of freeze-drying is 22-26 hours; the temperature of the second cross-linking is 20-30°C, and the time of the second cross-linking is 1.5-2.5 hours.

[0016] Preferably, when the first biopolymer material is oxidized hyaluronic acid, the method for preparing the porous magnetic scaffold comprises the following steps:

[0017] The oxidized hyaluronic acid solution, the first magnetic particle solution and the cross-linking agent are mixed for cross-linking, and freeze-dried after the cross-linking is completed to obtain a porous magnetic scaffold;

[0018] The mass fraction of the oxidized hyaluronic acid solution is 3-7%; the cross-linking agent is branched polyethyleneimine; the volume ratio of the oxidized hyaluronic acid solution to the first magnetic particle solution is 0.5-1.5:0.5-1.5; the volume ratio of the oxidized hyaluronic acid solution to the branched polyethyleneimine is 0.5-1.5:0.5-1.5;

[0019] The cross-linking temperature is 20 to 30° C., and the cross-linking time is 3 to 7 minutes; the freeze-drying temperature is -15 to -25° C., and the freeze-drying time is 22 to 26 hours.

[0020] Preferably, when the first biopolymer material is chitosan, the method for preparing the porous magnetic scaffold comprises the following steps:

[0021] The acetic acid solution of chitosan, the first magnetic particle solution and the cross-linking agent are mixed to perform cross-linking, and after the cross-linking is completed, self-assembly and freeze-drying are performed in sequence to obtain a porous magnetic scaffold;

[0022] The mass fraction of chitosan in the chitosan acetic acid solution is 5-7%; the cross-linking agent is glutaraldehyde solution, and the mass fraction of the glutaraldehyde solution is 2-4%; the volume ratio of the chitosan acetic acid solution, the first magnetic particle solution and the glutaraldehyde solution is 0.5-1.5:0.5-1.5:0.5-1.5;

[0023] The cross-linking temperature is 50-60°C, and the cross-linking time is 25-35 minutes; the self-assembly temperature is 20-30°C, and the self-assembly time is 46-50 hours; the freeze-drying temperature is -15--25°C, and the freeze-drying time is 22-26 hours.

[0024] Preferably, when the first biopolymer material is silk fibroin, the method for preparing the porous magnetic scaffold comprises the following steps:

[0025] The silk fibroin solution and the first magnetic particle solution are mixed and freeze-dried to obtain an intermediate substance after the freeze-drying is completed; the intermediate substance and a cross-linking agent are mixed and cross-linked to obtain a porous magnetic scaffold;

[0026] The mass fraction of the silk fibroin solution is 8-12%; the volume ratio of the silk fibroin solution to the first magnetic particle solution is 0.5-1.5:0.5-1.5; the crosslinking agent is methanol; the volume ratio of the silk fibroin solution to methanol is 0.5-1.5:2.5-3.5;

[0027] The freeze-drying temperature is -15 to -25°C, and the freeze-drying time is 22 to 26 hours; the cross-linking temperature is 20 to 30°C, and the cross-linking time is 1.5 to 2.5 hours.

[0028] Preferably, in step (1), the second biopolymer in the second biopolymer material solution comprises agarose or collagen; when the second biopolymer is agarose, the mass fraction of the second biopolymer solution is 1.5-2.5%; when the second biopolymer is collagen, the mass fraction of the second biopolymer solution is 8-12%;

[0029] The second magnetic particles in the second magnetic particle solution include iron-cobalt graphite nanocapsules, ferrite particles, neodymium-iron-boron particles, or alloy particles containing iron, cobalt, and nickel; the mass concentration of the second magnetic particle solution is 8 to 12 mg / mL;

[0030] The volume ratio of the second biopolymer solution to the second magnetic particle solution is 0.5-1.5:0.5-1.5;

[0031] In step (1), the heating temperature is 70-100° C. for 0.5-1.5 min, the self-assembly temperature is 20-30° C. for 25-35 min, and the freeze-drying temperature is -15--25° C. for 22-26 h.

[0032] Preferably, the volume ratio of the number of thermogenetic CXCL12 genetically engineered cells in step (2) to the porous magnetic support is 0.8×10 5 ~1.2×10 5 Piece: 80~120mm 3 ;

[0033] The co-incubation temperature is 35-40° C., and the co-incubation time is 5-15 min.

[0034] The present invention also provides an alginate-based thermogenetic CXCL12 releaser prepared by the preparation method.

[0035] The present invention also provides the use of the alginate-based thermogenetic CXCL12 releaser in the preparation of anti-tumor immune drugs or drugs for inhibiting peritoneal metastasis.

[0036] The beneficial effects of the present invention are:

[0037] The present invention utilizes transgenic and freeze-drying technologies to prepare an alginate-based thermogenetic CXCL12 releaser (ATCG) based on an optimized alternating magnetic field (AMF). The preparation is convenient and simple, and can be mass-produced. The ATCG is composed of a porous magnetic scaffold (IMS) loaded with engineered cells. The engineered cells are stably transfected with thermogenetic elements of pHSP70-CXCL12 by lentivirus. The porous magnetic scaffold has a main frame structure composed of a biopolymer material wrapped with magnetic particles, and has an isotropic porous structure. The ATCG prepared by the present invention can controllably release CXCL12 chemokines for DTC recruitment, and activate anti-DTC peritoneal immunity after magnetic thermal ablation, thereby inhibiting DTC peritoneal metastasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1This is a basic structural representation diagram of the IMS containing GFP engineered cells in Example 1 (Scaffold / Cell—scaffold / cell, Before washing—before washing, Afterwashing—after washing, Cell loading ratio—cell loading ratio); Figure 1 In the figure, a is a laser confocal microscopy characterization image of an IMS containing GFP engineered cells, b is a fluorescence imaging comparison image of an IMS containing GFP engineered cells and a P-IMS containing GFP engineered cells, c is a cell loading rate comparison image of an IMS and a P-IMS, d is a scanning electron microscopy characterization image of an IMS containing GFP engineered cells, and e is an element scanning characterization image of an IMS containing GFP engineered cells;

[0039] Figure 2 Characterization diagram of the magnetocaloric effect of IMS and ALG in Example 1 (Temperature—temperature, Time—time); Figure 2 In the figure, a is a comparison of infrared thermal imaging of IMS and ALG; b is a schematic diagram of the magnetothermal conversion capability of IMS under different alternating magnetic field intensities;

[0040] Figure 3 It is a characterization diagram of the thermal response ability of different cells in Example 1 and Implementation 2; Figure 3 In the above equation, a is GES-1 pHSP70-GFP Fluorescence characterization diagram after thermal stimulation, b is NIH-3T3 pHSP70-GFP Fluorescence characterization diagram after thermal stimulation, c is GES-1 pHSP70 -hCXCL12 WB characterization of CXCL12 protein after heat stimulation, d is NIH-3T3 pHSP70-mCXCL12 WB characterization of CXCL12 protein after heat stimulation;

[0041] Figure 4 It is a characterization diagram of the CXCL12 release ability after ATCG-1 magnetic heat treatment (Concentration of hCXCL12—hCXCL12 concentration, CXCL12 Relative Expression—CXCL12 expression level, Time—time); Figure 4 In the figure, a is a characterization diagram of ELISA data of CXCL12 protein secretion of ATCG-1 after magnetic thermal stimulation, b is a characterization diagram of qPCR data of CXCL12 gene expression of ATCG-1 after magnetic thermal stimulation, c is a schematic diagram of CXCL12 protein secretion kinetics of ATCG-1 after magnetic thermal stimulation, and d is a schematic diagram of CXCL12 gene expression kinetics of ATCG-1 after magnetic thermal stimulation;

[0042] Figure 5This is the evaluation diagram of the DTC chemotaxis ability of ATCG-1 (Transmigreted cell—chemotactic cell, Radiance—fluorescence intensity); Figure 5 In the middle, a is the effect of ATCG-1 on MGC-803 and MFC after magnetic thermal stimulation. mCxcr4 Transwell staining of cells, b is the chemotaxis statistical diagram of ATCG-1 to MGC-803 cells after magnetic thermal stimulation, and c is the chemotaxis statistical diagram of ATCG-1 to MGC-803 cells after magnetic thermal stimulation. mCxcr4 d is the fluorescence enzyme imaging diagram of ATCG-1 recruiting DTC in the peritoneal cavity of mice after magnetic thermal stimulation, and e is the fluorescence quantitative statistical diagram of ATCG-1 recruiting DTC in the peritoneal cavity of mice after magnetic thermal stimulation;

[0043] Figure 6 This is a graph evaluating the therapeutic effect of ATCG-2 in the peritoneal metastasis mouse model (Number of metastatic—metastatic number, Precent—percentage); Figure 6 In the figure, a is a CT three-dimensional imaging image of the mouse model of peritoneal metastasis after treatment with ATCG-2, b is a statistical graph of the number of peritoneal metastases after treatment with ATCG-2 in the mouse model of peritoneal metastasis, and c is a statistical graph of CD4 and CD8 T cells in the peritoneal cavity after treatment with ATCG-2 in the mouse model of peritoneal metastasis. DETAILED DESCRIPTION

[0044] The present invention provides a method for preparing an alginate-based thermogenetic CXCL12 releaser, comprising the following steps:

[0045] (1) mixing a first biopolymer material solution, a first magnetic particle solution and a cross-linking agent to perform cross-linking to obtain a porous magnetic scaffold;

[0046] Alternatively, the second biopolymer material solution and the second magnetic particle solution are mixed and heated, and after the heating is completed, self-assembly and freeze-drying are performed in sequence to obtain a porous magnetic scaffold;

[0047] (2) Adding thermogenetic CXCL12 genetically engineered cells to the surface of the porous magnetic support for co-incubation to obtain the alginate-based thermogenetic CXCL12 releaser.

[0048] In the present invention, the first biopolymer in the first biopolymer material solution in step (1) preferably includes sodium alginate, oxidized hyaluronic acid, chitosan or silk fibroin.

[0049] In the present invention, the first magnetic particles in the first magnetic particle solution preferably include iron-cobalt graphite nanocapsules, ferrite particles, neodymium-iron-boron particles or alloy particles containing iron, cobalt and nickel, and the solvent in the first magnetic particle solution is water; the mass concentration of the first magnetic particle solution is preferably 8 to 12 mg / mL, further preferably 9 to 11 mg / mL, and more preferably 10 to 10.5 mg / mL.

[0050] In the present invention, the preparation method of iron-cobalt graphite nanocapsules refers to patent CN115679472A (a magnetocaloric fiber, its preparation method and application); the ferrite particles are preferably a compound containing oxygen and iron, and are further preferably ferroferric oxide or ferric oxide; the preparation method of neodymium iron boron particles refers to the document Electronic Structure of NdFeCoB Oxide Magnetic Particles Studied by DFT Calculations and XPS-PMC (nih.gov); the preparation method of iron-cobalt-nickel alloy refers to the document Magnetic Graphitic Nanocapsules: Fabrication, Classification, and Theranostic Applications | Chemical & Biomedical Imaging (acs.org).

[0051] In the present invention, when the first biopolymer material is sodium alginate, the method for preparing the porous magnetic scaffold preferably comprises the following steps:

[0052] The sodium alginate solution, the first magnetic particle solution and the first cross-linking agent are mixed to perform a first cross-linking, and freeze-dried after the first cross-linking to obtain an intermediate substance; the intermediate substance and the second cross-linking agent are mixed to perform a second cross-linking to obtain a porous magnetic scaffold.

[0053] In the present invention, the solvent in the sodium alginate solution is water, and the mass fraction of the sodium alginate solution is preferably 1.5-2.5%, more preferably 1.7-2.3%, and more preferably 2-2.1%; the first cross-linking agent is preferably a calcium gluconate solution, the solvent in the calcium gluconate solution is water, and the mass fraction of the calcium gluconate solution is preferably 0.5-1.0%, more preferably 0.6-0.9%, and more preferably 0.7-0.8%; the second cross-linking agent is preferably a calcium chloride solution, the solvent in the calcium chloride solution is water, and the concentration of the calcium chloride solution is preferably 0.5- 1.5mol / L, further preferably 0.7-1.3mol / L, more preferably 0.8-1.0mol / L; the volume ratio of the sodium alginate solution, the first magnetic particle solution and the calcium gluconate solution is preferably 1-3:0.5-1.5:0.5-1.5, further preferably 1.5-2.5:0.7-1.3:0.7-1.3, more preferably 2-2.3:1-1.2:1-1.2; the present invention does not specifically limit the amount of calcium chloride solution, as long as it can ensure that the first biopolymer material is fully cross-linked.

[0054] In the present invention, the temperature of the first cross-linking is preferably 20-30°C, more preferably 22-28°C, and more preferably 25-26°C; the time of the first cross-linking is preferably 10-15 min, more preferably 11-14 min, and more preferably 12-13 min; the temperature of freeze-drying is preferably -15--25°C, more preferably -17--23°C, and more preferably -20--22°C; the time of freeze-drying is preferably 22-26 h, more preferably 23-25 ​​h, and more preferably 23.5-24 h; the temperature of the second cross-linking is preferably 20-30°C, more preferably 22-28°C, and more preferably 25-26°C; the time of the second cross-linking is preferably 1.5-2.5 h, more preferably 1.7-2.3 h, and more preferably 1.9-2 h.

[0055] In the present invention, after the second crosslinking is completed, the obtained sample is eluted with water to fully elute the uncrosslinked Ca 2+ , and obtain a porous magnetic scaffold, which was stored at 4°C.

[0056] In the present invention, when the first biopolymer material is oxidized hyaluronic acid, the method for preparing the porous magnetic scaffold preferably comprises the following steps:

[0057] The oxidized hyaluronic acid solution, the first magnetic particle solution and the cross-linking agent are mixed for cross-linking, and freeze-dried after the cross-linking is completed to obtain a porous magnetic scaffold.

[0058] In the present invention, the preparation method of oxidized hyaluronic acid preferably comprises the following steps:

[0059] Sodium periodate solution and hyaluronic acid solution are mixed, stirred in the dark at room temperature for preferably 1 to 3 hours, more preferably 1.5 to 2.5 hours, more preferably 2 hours, then ethylene glycol solution is added, and stirring is continued in the dark at room temperature for preferably 1 to 3 hours, more preferably 1.5 to 2.5 hours, more preferably 2 hours. After stirring, the mixture is transferred to a dialysis bag with a molecular weight cutoff of 3 kDa, and dialyzed with water for preferably 2 to 4 days, more preferably 2.5 to 3.5 days, more preferably 3 days. After dialysis, the mixture is freeze-dried using conventional techniques in the art to obtain oxidized hyaluronic acid.

[0060] In the present invention, the concentration of the sodium periodate solution is preferably 0.3-0.7 mol / L, more preferably 0.4-0.6 mol / L, and more preferably 0.5 mol / L; the mass fraction of the hyaluronic acid solution is preferably 0.5-1.5%, more preferably 0.7-1.3%, and more preferably 0.8-1.0%; the volume ratio of the sodium periodate solution to the hyaluronic acid solution is preferably 3-7:80-120, more preferably 4-6:90-110, and more preferably 5:100.

[0061] In the present invention, the solvent in the oxidized hyaluronic acid solution is water, and the mass fraction of the oxidized hyaluronic acid solution is preferably 3-7%, further preferably 4-6%, and more preferably 5-5.5%; the cross-linking agent is preferably branched polyethyleneimine; the volume ratio of the oxidized hyaluronic acid solution and the first magnetic particle solution is preferably 0.5-1.5:0.5-1.5, further preferably 0.7-1.3:0.7-1.3, and more preferably 1-1.2:1-1.2; the volume ratio of the oxidized hyaluronic acid solution and the branched polyethyleneimine is preferably 0.5-1.5:0.5-1.5, further preferably 0.7-1.3:0.7-1.3, and more preferably 1-1.2:1-1.2.

[0062] In the present invention, the cross-linking temperature is preferably 20 to 30°C, more preferably 22 to 28°C, and more preferably 25 to 26°C; the cross-linking time is preferably 3 to 7 min, more preferably 4 to 6 min, and more preferably 4.5 to 5 min; the freeze-drying temperature is preferably -15 to -25°C, more preferably -17 to -23°C, and more preferably -20 to -22°C; the freeze-drying time is preferably 22 to 26 h, more preferably 23 to 25 h, and more preferably 23.5 to 24 h; after freeze-drying, a porous magnetic scaffold is obtained and stored at 4°C.

[0063] In the present invention, when the first biopolymer material is chitosan, the method for preparing the porous magnetic scaffold preferably comprises the following steps:

[0064] The acetic acid solution of chitosan, the first magnetic particle solution and the cross-linking agent are mixed and cross-linked, and after the cross-linking is completed, self-assembly and freeze-drying are sequentially performed to obtain a porous magnetic scaffold.

[0065] In the present invention, the mass fraction of chitosan in the acetic acid solution of chitosan is preferably 5-7%, more preferably 5.5-6.5%, and more preferably 6-6.2%; the cross-linking agent is preferably a glutaraldehyde solution, the solvent in the glutaraldehyde solution is water, and the mass fraction of the glutaraldehyde solution is preferably 2-4%, more preferably 2.5-3.5%, and more preferably 3-3.2%; the volume ratio of the acetic acid solution of chitosan, the first magnetic particle solution and the glutaraldehyde solution is preferably 0.5-1.5:0.5-1.5:0.5-1.5, more preferably 0.7-1.3:0.7-1.3:0.7-1.3, and more preferably 1-1.2:1-1.2:1-1.2.

[0066] In the present invention, the cross-linking temperature is preferably 50-60°C, more preferably 52-58°C, and more preferably 55-56°C; the cross-linking time is preferably 25-35min, more preferably 27-33min, and more preferably 28-30min; the self-assembly temperature is preferably 20-30°C, more preferably 22-28°C, and more preferably 25-26°C; the self-assembly time is preferably 46-50h, more preferably 47-49h, and more preferably 47.5-48h; the freeze-drying temperature is preferably -15--25°C, more preferably -17--23°C, and more preferably -20--22°C; the freeze-drying time is preferably 22-26h, more preferably 23-25h, and more preferably 23.5-24h; after freeze-drying, a porous magnetic scaffold is obtained and stored at 4°C.

[0067] In the present invention, when the first biopolymer material is silk fibroin, the method for preparing the porous magnetic scaffold preferably comprises the following steps:

[0068] The silk fibroin solution and the first magnetic particle solution are mixed and freeze-dried to obtain an intermediate substance after the freeze-drying is completed; the intermediate substance and the cross-linking agent are mixed and cross-linked to obtain a porous magnetic scaffold.

[0069] In the present invention, the solvent in the silk fibroin solution is water, and the mass fraction of the silk fibroin solution is preferably 8-12%, further preferably 9-11%, and more preferably 10-10.5%; the volume ratio of the silk fibroin solution to the first magnetic particle solution is preferably 0.5-1.5:0.5-1.5, further preferably 0.7-1.3:0.7-1.3, and more preferably 1-1.2:1-1.2; the cross-linking agent is preferably methanol; the volume ratio of the silk fibroin solution to methanol is preferably 0.5-1.5:2.5-3.5, further preferably 0.7-1.3:2.7-3.3, and more preferably 1-1.2:3-3.2.

[0070] In the present invention, the freeze-drying temperature is preferably -15 to -25°C, more preferably -17 to -23°C, and more preferably -20 to -22°C; the freeze-drying time is preferably 22 to 26 hours, more preferably 23 to 25 hours, and more preferably 23.5 to 24 hours; the cross-linking temperature is preferably 20 to 30°C, more preferably -17 to -23°C, and more preferably -20 to -22°C; the cross-linking time is preferably 1.5 to 2.5 hours, more preferably 1.7 to 2.3 hours, and more preferably 1.9 to 2 hours.

[0071] In the present invention, after the cross-linking is completed, the obtained sample is eluted with water to obtain a porous magnetic scaffold, which is stored at 4°C.

[0072] In the present invention, the second biopolymer in the second biopolymer material solution in step (1) preferably includes agarose or collagen, and the solvent in the second biopolymer material solution is water; when the second biopolymer is agarose, the mass fraction of the second biopolymer solution is preferably 1.5-2.5%, more preferably 1.7-2.3%, and more preferably 2-2.1%; when the second biopolymer is collagen, the mass fraction of the second biopolymer solution is preferably 8-12%, more preferably 9-11%, and more preferably 10-10.5%.

[0073] In the present invention, the second magnetic particles in the second magnetic particle solution preferably include iron-cobalt graphite nanocapsules, ferrite particles, neodymium-iron-boron particles or alloy particles containing iron, cobalt and nickel. The source of the second magnetic particles is the same as that of the first magnetic particles. The solvent in the second magnetic particle solution is water. The mass concentration of the second magnetic particle solution is preferably 8 to 12 mg / mL, further preferably 9 to 11 mg / mL, and more preferably 10 to 10.5 mg / mL.

[0074] In the present invention, the volume ratio of the second biopolymer solution to the second magnetic particle solution is preferably 0.5-1.5:0.5-1.5, more preferably 0.7-1.3:0.7-1.3, and even more preferably 1-1.2:1-1.2.

[0075] In the present invention, the heating temperature in step (1) is preferably 70-100°C, more preferably 80-90°C, and more preferably 85-87°C; the time is preferably 0.5-1.5 min, more preferably 0.7-1.3 min, and more preferably 0.8-1 min; the self-assembly temperature is preferably 20-30°C, more preferably 22-28°C, and more preferably 25-26°C; the time is preferably 25-35 min, more preferably 27-33 min, and more preferably 28-30 min; the freeze-drying temperature is preferably -15--25°C, more preferably -17--23°C, and more preferably -20--22°C; the time is preferably 22-26 h, more preferably 23-25 ​​h, and more preferably 23.5-24 h; after freeze-drying, a porous magnetic scaffold is obtained and stored at 4°C.

[0076] In the present invention, the method for preparing thermogenetic CXCL12 genetically engineered cells in step (2) preferably comprises the following steps:

[0077] The central DNA plasmid (the central DNA plasmid is constructed with a promoter (marked as pHSP70) and the thermogenetic CXCL12 gene), packaging plasmid pMD2.G and packaging plasmid psPAX2 are transformed into 293T cells, and the lentivirus in the culture medium is collected 3 days after transfection. The lentivirus is then incubated with GES-1 or NIH-3T3 for 3 days. After the incubation, puromycin is added for 7 days of selection, and the cells that survive are the thermogenetic CXCL12 genetically engineered cells.

[0078] In the present invention, the thermogenetic CXCL12 gene sequence is obtained from the ncbi database. When the lentivirus is co-incubated with GES-1, the thermogenetic CXCL12 gene is hCXCL12; when the lentivirus is co-incubated with NIH-3T3, the thermogenetic CXCL12 gene is mCXCL12; the preparation method of the central DNA plasmid is seamless connection technology, which is a conventional process in the field; the references include Complete Chemical Synthesis, Assembly, and Cloning of a Mycoplasmagenitalium Genome|Science and Enzymatic assembly of DNA molecules up to several hundred kilobases|Nature Methods, and can also be purchased from GeneArt Seamless Cloning and Gibson |Thermo Fisher Scientific-CN; packaging plasmid pMD2.G and packaging plasmid psPAX2 were purchased from Addgene (the purchasing website for packaging plasmid pMD2.G is https: / / www.addgene.org / 12259 / , and the purchasing website for packaging plasmid psPAX2 is https: / / www.addgene.org / 12260 / ); 293T cells were purchased from ATCC (the purchasing website is https: / / www.atcc.org / products / crl-3216); GES-1 was purchased from ATCC; NIH-3T3 was purchased from Procell (the purchasing website is https: / / www.procell.com.cn / view / 8947.html).

[0079] In the present invention, the hCXCL12 gene sequence (SEQ ID NO.1) is:

[0080] ATGGACGCCAAGGTCGTCGCCGTGCTGGCCCTGGTGCTGGCCGCGCTCTGCATCAGTGACGGTAAACCAGTCAGCCTGAGCTACCGATGCCCCTGCCGGTTCTTCGAGAGCCACATCGCCAGAGCCAACGTCAAGCATCT GAAAATCCTCAACACTCCAAACTGTGCCCTTCAGATTGTTGCACGGCTGAAGAACAACAACAGACAAGTGTGCATTGACCCGAAATTAAAGTGGATCCAAGAGTACCTGGAGAAAGCTTTAAACAAGAGGCTCAAGATG.

[0081] In the present invention, the mCXCL12 gene sequence (SEQ ID NO.2) is:

[0082] ATGAACGCCAAGGTCGTGGTCGTGCTGGTCCTCGTGCTGACCGCGCTCTGCCTCAGCGACGGGAAGCCCGTCAGCCTGAGCTACAGATGCCCATGCCGATTCTTCGAAAGCCATGTTGCCAGAGCCAACGTCAAGCATCT CAAAATTCTCAACACTCCAAACTGTGCCCTTCAGATTGTAGCCCGGCTGAAGAACAACAGACAAGTGTGCATTGACCCGAAGCTAAAGTGGATTCAGGAGTACCTGGAGAAAGCTTTAAACAAGAGGTTCAAGATG.

[0083] In the present invention, the collection of lentivirus in the culture medium is completed by conventional technical means in the art, specifically, after the central DNA plasmid, packaging plasmid pMD2.G and packaging plasmid psPAX2 are transformed into 293T cells, the genes on these plasmids will begin to express, pMD2.G and psPAX2 will begin to express the protein shell of the lentivirus, these shells will assemble with the central DNA plasmid, and then the new generation of lentivirus will kill the host cells, the lentivirus will be released outside the cells, and then the lentivirus is collected by filtration and concentration; the temperature for incubating the lentivirus with GES-1 or NIH-3T3 is preferably 35-40°C, more preferably 36-39°C, and more preferably 37-38°C.

[0084] In the present invention, the volume ratio of the number of thermogenetic CXCL12 genetically engineered cells in step (2) to the porous magnetic support is preferably 0.8×105 ~1.2×10 5 Piece: 80~120mm 3 , and more preferably 0.9×10 5 ~1.1×10 5 Piece: 90~110mm 3 , more preferably 1×10 5 Piece: 100mm 3 .

[0085] In the present invention, in step (2), the thermogenetic CXCL12 genetically engineered cells are added to the surface of the porous magnetic support, specifically referring to dropping the thermogenetic CXCL12 genetically engineered cells onto the plane of the porous magnetic support (the porous magnetic support is cylindrical, and the plane of the porous magnetic support is the upper bottom surface or the lower bottom surface of the cylinder).

[0086] In the present invention, the co-incubation temperature is preferably 35-40°C, more preferably 36-39°C, and more preferably 37-38°C; the co-incubation time is preferably 5-15 min, more preferably 7-13 min, and more preferably 8-10 min.

[0087] The present invention also provides an alginate-based thermogenetic CXCL12 releaser prepared by the preparation method.

[0088] The present invention also provides the use of the alginate-based thermogenetic CXCL12 releaser in the preparation of anti-tumor immune drugs or drugs for inhibiting peritoneal metastasis.

[0089] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0090] Example 1

[0091] A 2% sodium alginate solution, a 10 mg / mL iron-cobalt graphite nanocapsule solution, and a 0.8% calcium gluconate solution (the volume ratio of the sodium alginate solution, the iron-cobalt graphite nanocapsule solution, and the calcium gluconate solution is 2:1:1) were mixed, cross-linked at 25°C for 12 min, and after the cross-linking was completed, freeze-dried at -20°C for 24 h, and then an excess of 1.0 mol / L calcium chloride solution was added, cross-linked at 25°C for 2 h, and after the cross-linking was completed, the obtained sample was eluted with water to fully elute the uncross-linked Ca 2+ , a porous magnetic scaffold (labeled as IMS) was obtained;

[0092] The central DNA plasmid (on which pHSP70 and thermogenetic hCXCL12 genes were constructed), packaging plasmid pMD2.G and packaging plasmid psPAX2 were transformed into 293T cells. The lentivirus in the culture medium was collected 3 days after transfection. The lentivirus was then incubated with GES-1 at 37°C for 3 days. After the incubation, puromycin was added for 7 days. The cells that survived were thermogenetic CXCL12 genetically engineered cells (labeled as GES-1 pHSP70-hCXCL12 );

[0093] 10 5 GES-1 pHSP70-hCXCL12 Add to volume 100mm 3 The alginate-based thermogenetic CXCL12 releaser (labeled as ATCG-1) was obtained by incubating the cells on the surface of the IMS at 37°C for 10 min.

[0094] The central DNA plasmid (pHSP70 and GFP were constructed on the central DNA plasmid, GFP is green fluorescent protein), packaging plasmid pMD2.G and packaging plasmid psPAX2 were transformed into 293T cells, and the lentivirus in the culture medium was collected 3 days after transfection. The lentivirus was then incubated with GES-1 at 37°C for 3 days. After the incubation, puromycin was added for 7 days, and the cells that finally survived were GFP engineered cells (i.e., GES-1 pHSP70-GFP ); 10 5 GFP engineered cells were added to a volume of 100 mm 3 The surface of the IMS prepared in this embodiment was incubated at 37°C for 10 minutes to obtain an IMS containing GFP engineered cells; at the same time, the IMS prepared in this embodiment was pressed with a 10g weight for 3 days to obtain a magnetic thermal non-porous scaffold (labeled as P-IMS); 10 5 GFP engineered cells were added to a volume of 100 mm 3on the surface of the P-IMS, and incubated at 37°C for 10 minutes to obtain the P-IMS containing GFP engineered cells. The IMS containing GFP engineered cells was placed under a laser confocal microscope for characterization, and the IMS containing GFP engineered cells and the P-IMS containing GFP engineered cells were photographed with a fluorescence imaging system. After photographing, they were washed with DPBS three times respectively, and then photographed again with a fluorescence imaging system after washing; and the cell loading rate of IMS and P-IMS was quantified by the signal intensity of GFP; finally, the IMS containing GFP engineered cells was fixed on the conductive glue, and gold was sprayed for 90s to improve the conductivity. The surface microstructure was observed by a scanning electron microscope (TESCAN) at an accelerating voltage of 20kV, and element scanning analysis was performed using an X-ray energy dispersion spectrometer; the basic structural characterization diagram of the IMS containing GFP engineered cells in Example 1 was obtained, as shown Figure 1 As shown (Scaffold / Cell—scaffold / cell, Before washing—before washing, After washing—after washing, Cell loading ratio—cell loading ratio); Figure 1 In the figure, a is a laser confocal microscopy characterization image of an IMS containing GFP engineered cells, b is a fluorescence imaging comparison image of an IMS containing GFP engineered cells and a P-IMS containing GFP engineered cells, c is a cell loading rate comparison image of an IMS and a P-IMS, d is a scanning electron microscopy characterization image of an IMS containing GFP engineered cells, and e is an element scanning characterization image of an IMS containing GFP engineered cells. Figure 1 It can be seen that there are a large number of engineered cells in the IMS containing GFP engineered cells, and these cells are effectively maintained in the void structure of the IMS; the IMS containing GFP engineered cells can effectively load cells inside the scaffold due to the porous structure, and the cell loading rate of the IMS can reach 82.2±16.6%, which can reach 13.05 times that of P-IMS; the IMS containing GFP engineered cells can see that the cells exist in the scaffold, and the scaffold contains carbon, iron, and cobalt elements. In summary, there are a large number of engineered cells and carbon, iron, and cobalt elements in the IMS containing GFP engineered cells, which indicates the successful preparation of the IMS containing GFP engineered cells.

[0095] A 2% sodium alginate solution and a 0.8% calcium gluconate solution (the volume ratio of the sodium alginate solution to the calcium gluconate solution is 2:1) were mixed, cross-linked at 25°C for 12 minutes, and after the cross-linking was completed, freeze-dried at -20°C for 24 hours, and then an excess of 1.0 mol / L calcium chloride solution was added, cross-linked at 25°C for 2 hours. After the cross-linking was completed, the obtained sample was eluted with water to fully elute the uncross-linked Ca 2+, a stent without doping with magnetocaloric material (labeled as ALG) was obtained; IMS and ALG were exposed to a coil with a diameter of 60 mm, respectively, and the entire heating process was monitored using an infrared thermal imager (FOTRIC 365) at a frequency of 340 kHz and a magnetic field strength of 60% (corresponding to an alternating magnetic field of 27 kA / m); in addition, in order to optimize the heating effect of IMS, the magnetocaloric conversion capacity of IMS under different alternating magnetic field strengths (40% to 60% magnetic field strength, corresponding to an alternating magnetic field of 18 to 27 kA / m) was monitored; the magnetocaloric effect characterization diagram of IMS and ALG in Example 1 was obtained, as shown Figure 2 As shown (Temperature—temperature, Time—time); Figure 2 In the figure, a is a comparison of infrared thermal imaging of IMS and ALG; b is a schematic diagram of the magnetothermal conversion capability of IMS under different alternating magnetic field strengths (60% refers to an alternating magnetic field of 27 kA / m, 50% refers to an alternating magnetic field of 22.5 kA / m, 45% refers to an alternating magnetic field of 20.25 kA / m, and 40% refers to an alternating magnetic field of 18 kA / m). Figure 2 It can be seen that compared with ALG, IMS has a significant warming effect under an alternating magnetic field. By adjusting the alternating magnetic field strength where IMS is located, the warming effect of IMS can be effectively adjusted. The higher the alternating magnetic field strength, the faster the IMS warming rate. It has been measured that the IMS warming rate can reach 0.1-0.3℃ / s. It can be heated to about 45℃ under an alternating magnetic field of 22.5kA / m, and can be heated to about 55℃ under an alternating magnetic field of 27kA / m. Among them, 45℃ can be used for thermal activation of thermogenetic CXCL12 genetically engineered cells, and 55℃ can be used for DTC-derived TAA (tumor-associated antigen) release and peritoneal immune activation. The above data show that IMS has significant magnetothermal response ability, and the magnetothermal warming effect can be adjusted by adjusting the alternating magnetic field strength, and it has good magnetothermal effect and controllability.

[0096] Example 2

[0097] The other conditions for preparing ATCG-1 in Example 1 were controlled unchanged, and the thermogenetic hCXCL12 gene was replaced with the thermogenetic mCXCL12 gene, and GES-1 was replaced with NIH-3T3 to obtain NIH-3T3. pHSP70-mCXCL12 ;

[0098] 10 5 NIH-3T3 pHSP70-mCXCL12 Add to volume 100mm 3 The alginate-based thermogenetic CXCL12 releaser (labeled as ATCG-2) was obtained by incubating the cells on the surface of the IMS at 37°C for 10 min.

[0099] The central DNA plasmid (pHSP70 and GFP were constructed on the central DNA plasmid, GFP is green fluorescent protein), packaging plasmid pMD2.G and packaging plasmid psPAX2 were transformed into 293T cells, and the lentivirus in the culture medium was collected 3 days after transfection. The lentivirus was then incubated with NIH-3T3 at 37°C for 3 days. After the incubation, puromycin was added for 7 days, and the cells that survived were NIH-3T3. pHSP70-GFP ; GES-1 prepared in Example 1 pHSP70-GFP and the NIH-3T3 prepared in this example pHSP70-GFP For visualization of engineered cells, characterization of GES-1 using confocal laser scanning microscopy pHSP70-GFP and NIH-3T3 pHSP70-GFP After stimulation at 45°C for 12 hours, the expression of GFP was increased. pHSP70 -hCXCL12 and the NIH-3T3 prepared in this example pHSP70-mCXCL12 Used for characterization of protein secretion of thermogenetic CXCL12 genetically engineered cells and WB detection of GES-1 pHSP70-hCXCL12 and NIH-3T3 pHSP70-mCXCL12 The protein secretion capacity of CXCL12 after stimulation at 45°C for 12 hours; the thermal response capacity characterization diagram of different cells in Example 1 and Example 2 is obtained, as shown in Figure 3 As shown; Figure 3 In the above equation, a is GES-1 pHSP70-GFP Fluorescence characterization diagram after thermal stimulation, b is NIH-3T3 pHSP70-GFP Fluorescence characterization diagram after thermal stimulation, c is GES-1 pHSP70-hCXCL12 WB characterization of CXCL12 protein after heat stimulation, d is NIH-3T3 pHSP70 -mCXCL12 Western blot characterization of CXCL12 protein after heat stimulation. In a, GES-1 is a single human cell GES-1, GES-1 pHSP70-GFP GES-1 prepared in Example 1 pHSP70-GFP , GES-1 pHSP70-GFP +heat is GES-1 after heat stimulation pHSP70-GFP , BF is the abbreviation of Bright Field, which means bright field; in b, 3T3 is a single mouse cell NIH-3T3, 3T3 pHSP70-GFP NIH-3T3 prepared in Example 2 pHSP70-GFP ,3T3 pHSP70-GFP +heat is NIH-3T3 after heat stimulation pHSP70-GFPIn c, Control is a control group, i.e., a single human cell GES-1 without any manipulation, and pHSP70-hCXCL12 is the GES-1 prepared in Example 1. pHSP70-hCXCL12 , pHSP70-hCXCL12+heat is GES-1 after heat stimulation pHSP70-hCXCL12 , GAPDH is the internal reference gene; in d, Control is the control group, i.e., a single mouse cell NIH-3T3 without any manipulation, and pHSP70-mCXCL12 is the NIH-3T3 prepared in Example 2 pHSP70-mCXCL12 , pHSP70-mCXCL12+heat is NIH-3T3 after heat stimulation pHSP70-mCXCL12 , GAPDH is the internal reference gene). Figure 3 As can be seen, GES-1 pHSP70-GFP and NIH-3T3 pHSP70-GFP Under heat stimulation, GES-1 showed significant GFP expression. pHSP70-hCXCL12 and NIH-3T3 pHSP70-mCXCL12 CXCL12 was successfully expressed and secreted, indicating that the cells effectively promoted the expression of CXCL12 chemokine under heat stimulation. The above data show that thermogenetic engineered cells have obvious heat response ability and can effectively promote the expression of GFP and CXCL12 under 45°C stimulation.

[0100] The ATCG-1 prepared in Example 1 was exposed to a coil with a diameter of 60 mm, and subjected to magnetic heat treatment for 10 min at a frequency of 340 kHz and an alternating magnetic field of 22.5 kA / m. After the treatment, the ATCG-1 was placed in a 37°C, 5% CO2 incubator (the mass fraction of CO2 in the culture medium to air was 5%) for 12 h, and the culture medium was collected for ELISA (enzyme-linked immunosorbent assay) to detect the concentration of CXCL12. In addition, the cells in the scaffold were collected to extract RNA, and the expression level of the CXCL12 gene was detected by qPCR (real-time fluorescence quantitative analysis), and a characterization diagram of the CXCL12 release ability of ATCG-1 after magnetic heat treatment was obtained, as shown in FIG. Figure 4 As shown (Concentration of hCXCL12—hCXCL12 concentration, CXCL12 Relative Expression—CXCL12 expression level, Time—time); Figure 4In the figure, a is the ELISA data representation of CXCL12 protein secretion of ATCG-1 after magnetic thermal stimulation, b is the qPCR data representation of CXCL12 gene expression of ATCG-1 after magnetic thermal stimulation, c is the schematic diagram of CXCL12 protein secretion kinetics of ATCG-1 after magnetic thermal stimulation, and d is the schematic diagram of CXCL12 gene expression kinetics of ATCG-1 after magnetic thermal stimulation. In a, 1, 2, 3, and 5 in the horizontal axis are the control group, and 4 is the experimental group; specifically, 1 is 10 5 GES-1 is added to a volume of 100mm 3 10 and 10 were incubated at 37°C for 10 min to obtain IMS containing GES-1 without magnetic thermal treatment; 20 was 10 5 GES-1 is added to a volume of 100mm 3 on the surface of the IMS, incubated at 37°C for 10 minutes to obtain an IMS containing GES-1, and the IMS containing GES-1 was subjected to magnetic thermal treatment using the same method as above; 3 is the ATCG-1 prepared in Example 1, which was not subjected to magnetic thermal treatment; 4 is the experimental group recorded above, that is, the ATCG-1 prepared in Example 1 was subjected to magnetic thermal treatment; 5 is the hCXCL12 protein inhibitor added to the ATCG-1 prepared in Example 1 after magnetic thermal treatment; the meaning of the horizontal axis in b is the same as that in a; in c, ATCG-1+AMF is the ATCG-1 prepared in Example 1 subjected to magnetic thermal treatment, and ATCG-1 is the ATCG-1 prepared in Example 1 without magnetic thermal treatment; d is the same as c. Figure 4 It can be seen that ATCG-1 can secrete CXCL12 protein at a concentration of 1.73±0.11ng / mL 12h after thermal stimulation, which is 34.6 times that of the control group (1), and the CXCL12 gene expression level is 601.09 times that of the control group (1). In addition, the inhibitor treatment has little effect on the gene expression and protein secretion of CXCL12 of ATCG-1; the protein concentration of ATCG-1 reaches a peak 24h after magnetic thermal stimulation, and the gene expression reaches a peak 8h after thermal stimulation. After 48h, the protein secretion and gene expression can be reversibly restored to the pre-stimulation level. The above data show that ATCG-1 has obvious thermal response ability. Under magnetic thermal stimulation, it can effectively promote CXCL12 protein secretion and gene expression, and reversibly restore to the pre-stimulation level after 48h.

[0101] The ATCG-1 prepared in Example 1 was co-incubated with human gastric cancer cells MGC-803 in Transwell in vitro, and thermally stimulated for 10 minutes under an alternating magnetic field of 22.5 kA / m. After the thermal stimulation, the cells were left for 3 days, the Transwell was taken out, washed 3 times with DPBS, and then stained with an aqueous solution of crystal violet with a mass fraction of 0.1% for 5 minutes. The upper cells of the Transwell were gently wiped with a cotton swab, and then the cells were observed under an optical microscope, and the number of cells was counted with ImageJ. The above conditions were kept unchanged, and the ATCG-1 prepared in Example 1 was replaced by the ATCG-2 prepared in Example 2, and the human gastric cancer cells MGC-803 were replaced by the mouse gastric cancer cells MFC mCxcr4 Finally, the number of cells was counted using ImageJ. On the other hand, an experimental peritoneal metastasis model was established in 8-week-old female nude mice. 5 Human gastric cancer cells MGC-803 were transplanted into the abdominal cavity of nude mice. Three days later, ATCG-1 was transplanted into the abdominal cavity of nude mice and then exposed to a 60 mm diameter coil, a frequency of 340 kHz, and an alternating magnetic field of 22.5 kA / m. The mice were subjected to magnetic heat treatment for 10 min. One day later, the mice were subjected to magnetic heat treatment for 10 min under the same conditions. On the seventh day, ATCG-1 was removed from the abdominal cavity and imaged using a fluorescence imaging system (seven parallel experiments were performed). Subsequently, the fluorescence intensity was quantified using software (average value was taken) to obtain an evaluation graph of the DTC chemotaxis ability of ATCG-1, as shown in FIG. Figure 5 As shown (Transmigreted cell—chemotactic cell, Radiance—fluorescence intensity); Figure 5 In the middle, a is the effect of ATCG-1 on MGC-803 and MFC after magnetic thermal stimulation. mCxcr4 Transwell staining of cells, b is the chemotaxis statistical diagram of ATCG-1 to MGC-803 cells after magnetic thermal stimulation, and c is the chemotaxis statistical diagram of ATCG-1 to MGC-803 cells after magnetic thermal stimulation. mCxcr4 d is the fluorescence enzyme imaging of ATCG-1 recruiting DTC in the mouse peritoneal cavity after magnetic thermal stimulation, and e is the fluorescence quantitative statistical diagram of ATCG-1 recruiting DTC in the mouse peritoneal cavity after magnetic thermal stimulation. 5 GES-1 is added to a volume of 100mm 3 10 and 10 min at 37°C to obtain IMS containing GES-1 without thermal stimulation; 20 5 GES-1 is added to a volume of 100mm 31 is the ATCG-1 prepared in Example 1, which is not subjected to thermal stimulation; 2 is the ATCG-1 prepared in Example 1, which is subjected to thermal stimulation; 3 is the ATCG-1 prepared in Example 1, which is subjected to thermal stimulation; 4 is the ATCG-1 prepared in Example 1, which is subjected to thermal stimulation; 5 is the addition of hCXCL12 protein inhibitor to the ATCG-1 prepared in Example 1, and 6 is the addition of hCXCL12 protein inhibitor to the ATCG-1 prepared in Example 1; 5 NIH-3T3 was added to a volume of 100 mm 3 on the surface of the IMS, and incubated at 37°C for 10 min to obtain the IMS containing NIH-3T3 without thermal stimulation; 7 is 10 5 NIH-3T3 was added to a volume of 100 mm 3 on the surface of the IMS, incubated at 37°C for 10 min to obtain the IMS containing NIH-3T3, and the IMS containing NIH-3T3 was subjected to thermal stimulation using the same method as above; 8 is the ATCG-2 prepared in Example 2, which was not subjected to thermal stimulation; 9 is the ATCG-2 prepared in Example 2 subjected to thermal stimulation; 10 is the addition of hCXCL12 protein inhibitor on the basis of thermal stimulation of the ATCG-2 prepared in Example 2; the abscissas in b and c have the same meaning as the corresponding marks in a; in d, GES-1 is 10 5 GES-1 is added to a volume of 100mm 3 The IMS was incubated at 37°C for 10 min to obtain an IMS group containing GES-1; GES-1 CXCL12 The ATCG-1 group prepared in Example 1; GES-1 CXCL12 +AMF is a group subjected to magnetic heat treatment based on ATCG-1 prepared in Example 1; e is the same as d, and the ordinate in e is 1*10 09 That is 1*10 9 , 5*10 08 That is 5*10 8 .from Figure 5 It can be found that in the in vitro Transwell co-culture system, ATCG-1 and ATCG-2 have an inhibitory effect on the growth of human gastric cancer cells MGC-803 and mouse gastric cancer cells MFC after 3 days of heat stimulation. mCxcr4It has a significant chemotactic effect. The quantification of chemotactic cells shows that the effect can reach 5.56 to 7.53 times that of the control group (1 and 6), and after inhibitor treatment, the DTC chemotactic level is significantly inhibited; after 7 days of magnetic heat stimulation in vivo, ATCG-1 has a significant recruitment ability for MGC-803 cells and induces intraperitoneal DTC to colonize on the ATCG-1 scaffold. After quantification of fluorescence intensity, it shows that the effect can reach 14.05 times that of the control group (GES-1). The above data show that ATCG can have significant chemotactic and recruitment abilities for gastric cancer cells in vitro and in vivo, and induce tumor cells to colonize on the scaffold.

[0102] 3 days in advance 5 Mouse gastric cancer cell MFC mCxcr4 The mice were injected into the peritoneal cavity to construct an immune-competent experimental peritoneal metastasis model. ATCG-2 was then transplanted into the peritoneal cavity of mice. On the first and third days, the mice were exposed to a 60 mm diameter coil, a frequency of 340 kHz, and an alternating magnetic field of 22.5 kA / m (the temperature can be raised to about 45°C under an alternating magnetic field of 22.5 kA / m), and magnetically heated for 10 minutes to induce ATCG-2 to secrete chemokine CXCL12 to recruit intraperitoneal DTCs. On the fifth and seventh days, the mice were exposed to a 60 mm diameter coil, a frequency of 340 kHz, and an alternating magnetic field of 27 kA / m (the temperature can be raised to about 55°C under an alternating magnetic field of 27 kA / m), and magnetically heated for 10 minutes to induce ATCG-2 to produce a high temperature environment to damage DTCs and release TAA. After day 14, the mice were imaged using the IVIS-CT system, and the peritoneal fluid was collected from the mice. CD4-positive and CD8-positive T cells were analyzed using flow cytometry to obtain an evaluation chart of the therapeutic effect of ATCG-2 in the peritoneal metastasis mouse model, as shown in the figure below. Figure 6 As shown (Number of metastatic—number of transfers, Precent—percentage); Figure 6 In the figure, a is a CT three-dimensional image of ATCG-2 in the mouse model of abdominal metastasis after treatment, b is a statistical diagram of the number of peritoneal metastases after ATCG-2 in the mouse model of abdominal metastasis, and c is a statistical diagram of CD4 and CD8 T cells in the peritoneal cavity after ATCG-2 in the mouse model of abdominal metastasis. In a, Control is only 10 5 Mouse gastric cancer cell MFC mCxcr4 injected into the abdominal cavity of mice without any treatment; 3T3 was 10 5 NIH-3T3 was added to a volume of 100 mm 3 The MFC was placed on the surface of the IMS and incubated at 37°C for 10 min to obtain the IMS containing NIH-3T3. mCxcr4After injection into the mouse peritoneal cavity, the IMS containing NIH-3T3 was transplanted into the mouse peritoneal cavity; 3T3 12 To MFC mCxcr4 After injection into the mouse peritoneal cavity, ATCG-2 was transplanted into the mouse peritoneal cavity group; 3T3 12 45AMF is MFC mCxcr4 After injection into the peritoneal cavity of mice, ATCG-2 was transplanted into the peritoneal cavity of mice, and then the mice were exposed to a 60 mm diameter coil, a frequency of 340 kHz, and an alternating magnetic field of 22.5 kA / m for 10 min of magnetic heat treatment on the first and third days to induce ATCG-2 to secrete the chemokine CXCL12 to recruit DTCs in the peritoneal cavity; 3T3 12 55AMF is MFC mCxcr4 After injection into the peritoneal cavity of mice, ATCG-2 was transplanted into the peritoneal cavity of mice, and then on the 5th and 7th days, the mice were exposed to a 60mm diameter coil, a frequency of 340kHz, and an alternating magnetic field of 27kA / m for 10min of magnetic heat treatment to induce ATCG-2 to produce a high temperature environment to damage DTC and release TAA group; 3T3 12 45AMF55AMF are the experimental groups described above; the meanings of the symbols in b and c are the same as in a. Figure 6 It can be seen that after ATCG-2 treatment, IVIS-CT imaging results showed that ATCG-2 can effectively reduce the number of abdominal metastases, and the quantitative results showed that it can reduce the level of abdominal metastases by 6.09 times; the number of CD4-positive cells in the abdominal cavity changed little, while CD8-positive T cells increased significantly by 1.8 times in the ATCG-2 treatment group. The above data show that ATCG-2 can effectively reduce peritoneal metastasis and effectively activate the level of peritoneal immunity, realizing intraperitoneal immunotherapy for DTC.

[0103] It can be seen from the above embodiments that the present invention provides an alginate-based thermogenetic CXCL12 releaser (ATCG) based on an optimized alternating magnetic field (AMF) prepared by using transgenic and freeze-drying technology. The preparation is convenient and simple, and can be produced on a large scale. The ATCG is composed of a porous magnetic scaffold (IMS) loaded with engineered cells, and the engineered cells are stably transfected with the thermogenetic elements of pHSP70-CXCL12 by lentivirus. The porous magnetic scaffold is composed of a main frame structure composed of a biopolymer material wrapped with magnetic particles, and has an isotropic porous structure. The ATCG prepared by the present invention can controllably release CXCL12 chemokines for DTC recruitment, and activate anti-DTC peritoneal immunity after magnetic thermal ablation, thereby inhibiting DTC peritoneal metastasis.

[0104] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for preparing an alginate-based thermogenetic CXCL12 releaser, characterized in that: It includes the following steps: (1) mixing a first biopolymer material solution, a first magnetic particle solution and a cross-linking agent to perform cross-linking to obtain a porous magnetic scaffold; Alternatively, the second biopolymer material solution and the second magnetic particle solution are mixed and heated, and after the heating is completed, self-assembly and freeze-drying are performed in sequence to obtain a porous magnetic scaffold; (2) Adding thermogenetic CXCL12 genetically engineered cells to the surface of the porous magnetic support for co-incubation to obtain the alginate-based thermogenetic CXCL12 releaser.

2. The method for preparing the alginate-based thermogenetic CXCL12 releaser according to claim 1, characterized in that: Step (1) the first biopolymer material solution contains a first biopolymer comprising sodium alginate, oxidized hyaluronic acid, chitosan or silk fibroin; The first magnetic particles in the first magnetic particle solution include iron-cobalt graphite nanocapsules, ferrite particles, neodymium-iron-boron particles or alloy particles containing iron, cobalt and nickel; the mass concentration of the first magnetic particle solution is 8-12 mg / mL.

3. The method for preparing the alginate-based thermogenetic CXCL12 releaser according to claim 2, characterized in that: When the first biopolymer material is sodium alginate, the method for preparing the porous magnetic scaffold comprises the following steps: The sodium alginate solution, the first magnetic particle solution and the first cross-linking agent are mixed to perform a first cross-linking, and after the first cross-linking is completed, freeze-dried to obtain an intermediate substance; the intermediate substance is mixed with a second cross-linking agent to perform a second cross-linking to obtain a porous magnetic scaffold; The mass fraction of the sodium alginate solution is 1.5-2.5%; the first cross-linking agent is a calcium gluconate solution, the mass fraction of the calcium gluconate solution is 0.5-1.0%; the second cross-linking agent is a calcium chloride solution, the concentration of the calcium chloride solution is 0.5-1.5 mol / L; the volume ratio of the sodium alginate solution, the first magnetic particle solution and the calcium gluconate solution is 1-3:0.5-1.5:0.5-1.5; The temperature of the first cross-linking is 20-30°C, and the time of the first cross-linking is 10-15 minutes; the temperature of freeze-drying is -15--25°C, and the time of freeze-drying is 22-26 hours; the temperature of the second cross-linking is 20-30°C, and the time of the second cross-linking is 1.5-2.5 hours.

4. The method for preparing the alginate-based thermogenetic CXCL12 releaser according to claim 2, characterized in that: When the first biopolymer material is oxidized hyaluronic acid, the method for preparing the porous magnetic scaffold comprises the following steps: The oxidized hyaluronic acid solution, the first magnetic particle solution and the cross-linking agent are mixed for cross-linking, and freeze-dried after the cross-linking is completed to obtain a porous magnetic scaffold; The mass fraction of the oxidized hyaluronic acid solution is 3-7%; the cross-linking agent is branched polyethyleneimine; the volume ratio of the oxidized hyaluronic acid solution to the first magnetic particle solution is 0.5-1.5:0.5-1.5; the volume ratio of the oxidized hyaluronic acid solution to the branched polyethyleneimine is 0.5-1.5:0.5-1.5; The cross-linking temperature is 20 to 30° C., and the cross-linking time is 3 to 7 minutes; the freeze-drying temperature is -15 to -25° C., and the freeze-drying time is 22 to 26 hours.

5. The method for preparing the alginate-based thermogenetic CXCL12 releaser according to claim 2, characterized in that: When the first biopolymer material is chitosan, the method for preparing the porous magnetic scaffold comprises the following steps: The acetic acid solution of chitosan, the first magnetic particle solution and the cross-linking agent are mixed to perform cross-linking, and after the cross-linking is completed, self-assembly and freeze-drying are performed in sequence to obtain a porous magnetic scaffold; The mass fraction of chitosan in the chitosan acetic acid solution is 5-7%; the cross-linking agent is glutaraldehyde solution, and the mass fraction of the glutaraldehyde solution is 2-4%; the volume ratio of the chitosan acetic acid solution, the first magnetic particle solution and the glutaraldehyde solution is 0.5-1.5:0.5-1.5:0.5-1.5; The cross-linking temperature is 50-60°C, and the cross-linking time is 25-35 minutes; the self-assembly temperature is 20-30°C, and the self-assembly time is 46-50 hours; the freeze-drying temperature is -15--25°C, and the freeze-drying time is 22-26 hours.

6. The method for preparing the alginate-based thermogenetic CXCL12 releaser according to claim 2, characterized in that: When the first biopolymer material is silk fibroin, the method for preparing the porous magnetic scaffold comprises the following steps: The silk fibroin solution and the first magnetic particle solution are mixed and freeze-dried to obtain an intermediate substance after the freeze-drying is completed; the intermediate substance and a cross-linking agent are mixed and cross-linked to obtain a porous magnetic scaffold; The mass fraction of the silk fibroin solution is 8-12%; the volume ratio of the silk fibroin solution to the first magnetic particle solution is 0.5-1.5:0.5-1.5; the crosslinking agent is methanol; the volume ratio of the silk fibroin solution to methanol is 0.5-1.5:2.5-3.5; The freeze-drying temperature is -15 to -25°C, and the freeze-drying time is 22 to 26 hours; the cross-linking temperature is 20 to 30°C, and the cross-linking time is 1.5 to 2.5 hours.

7. The method for preparing the alginate-based thermogenetic CXCL12 releaser according to claim 1, characterized in that: Step (1) the second biopolymer in the second biopolymer material solution comprises agarose or collagen; when the second biopolymer is agarose, the mass fraction of the second biopolymer solution is 1.5-2.5%; when the second biopolymer is collagen, the mass fraction of the second biopolymer solution is 8-12%; The second magnetic particles in the second magnetic particle solution include iron-cobalt graphite nanocapsules, ferrite particles, neodymium-iron-boron particles, or alloy particles containing iron, cobalt, and nickel; the mass concentration of the second magnetic particle solution is 8 to 12 mg / mL; The volume ratio of the second biopolymer solution to the second magnetic particle solution is 0.5-1.5:0.5-1.5; In step (1), the heating temperature is 70-100° C. for 0.5-1.5 min, the self-assembly temperature is 20-30° C. for 25-35 min, and the freeze-drying temperature is -15--25° C. for 22-26 h.

8. The method for preparing the alginate-based thermogenetic CXCL12 releaser according to claim 7, characterized in that:The volume ratio of the number of thermogenetic CXCL12 genetically engineered cells in step (2) to the porous magnetic scaffold is 0.8×10 5 ~1.2×10 5 Piece: 80~120mm 3 ; The co-incubation temperature is 35-40° C., and the co-incubation time is 5-15 min.

9. The alginate-based thermogenetic CXCL12 releaser prepared by the preparation method according to any one of claims 1 to 8.

10. Use of the alginate-based thermogenetic CXCL12 releaser according to claim 9 in the preparation of anti-tumor immune drugs or drugs for inhibiting peritoneal metastasis.

Citation Information

Patent Citations

  • Immune Cell Trapping Devices And Methods For Making And Using The Same

    CN107708756A

  • Magnetic graphene nanocapsule as well as preparation method and application thereof

    CN115645531A

  • Alginate capsules for use in the treatment of brain tumor

    CN1320032A

  • Dry microcarrier and method for producing the same

    JP2024072649A

  • Cancer Cell Trap

    US20150283073A1